Summit Therapeutics (SMMT) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Summit Therapeutics (NASDAQ: SMMT):

  • 11/18/2026 – Summit Therapeutics was downgraded by Sanford C. Bernstein from “market perform” to “underperform”. They now have a $8.30 price target on the stock, down from $11.90.
  • 11/16/2026 – Summit Therapeutics had its price target lowered by Citigroup from $43.00 to $42.00. They now have a “buy” rating on the stock.
  • 11/16/2026 – Summit Therapeutics had its price target lowered by Barclays from $20.00 to $18.00. They now have an “equal weight” rating on the stock.
  • 11/15/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group.
  • 10/27/2026 – Summit Therapeutics had its “market outperform” rating reaffirmed by Citigroup.
  • 10/26/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group.
  • 10/15/2026 – Summit Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/15/2026 – Summit Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
  • 10/5/2026 – Summit Therapeutics had its “market perform” rating reaffirmed by Sanford C. Bernstein.
  • 10/1/2026 – Summit Therapeutics had its price target raised by Barclays from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
  • 9/30/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
  • 9/29/2026 – Summit Therapeutics was given a new $41.00 price target by The Goldman Sachs Group. They now have a “buy” rating on the stock.
  • 9/29/2026 – Summit Therapeutics was downgraded by Morgan Stanley to “outperform”.
  • 9/29/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $30.00 price target on the stock.
  • 9/25/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Citigroup. They now have a $43.00 price target on the stock, up from $40.00.
  • 9/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by UBS Group.
  • 9/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
  • 9/22/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.

Summit Therapeutics Price Performance

SMMT traded down $0.16 during midday trading on Wednesday, reaching $10.51. 10,043,926 shares of the company’s stock were exchanged, compared to its average volume of 4,799,099. Summit Therapeutics PLC has a 1-year low of $10.14 and a 1-year high of $29.23. The stock has a market capitalization of $8.40 billion, a PE ratio of -9.82 and a beta of -1.49. The business’s 50-day moving average price is $16.16 and its 200 day moving average price is $16.09.

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.

Read More

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.